Excelera® and Aptitude Health Partner to Improve Oncology Patient Outcomes Through Combined Clinical Knowledge and Educationhttps://shieldshealthsolutions.com/content/uploads/2021/06/shields-blog-icon-pr-1.svg204115Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Wolfe joins Excelera with significant experience in building strategic pharmaceutical manufacturer relationships for publicly traded and private organizations in the healthcare sector
New Combination Therapies for the Treatment of Chronic Lymphocytic Leukemiahttps://shieldshealthsolutions.com/content/themes/blade/images/empty/thumbnail.jpg150150Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Erin Kelley, PharmD, BCOP, and Jeff Engle, PharmD, MS, Fairview Health
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) is the most common type of leukemia in adults and accounts for approximately 37% of new leukemia cases. An estimated 20,720 new cases of and 3930 deaths from CLL will occur in the United States in 2019.